Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: Open-End Fund
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: Global

Danske Invest-Bioteknologi Fund

+ Add to Watchlist

DANIBIO:DC

290.6000 DKK 3.0000 1.04%

As of 11:00:00 ET on 04/24/2015.

Snapshot for Danske Invest-Bioteknologi Fund (DANIBIO)

Open: 289.9000 High - Low: 292.2000 - 288.5000 Primary Exchange: Copenhagen
Volume: 69,293 52-Week Range: 164.1000 - 372.7000 Beta vs BTK: 0.9887

ETF Chart for DANIBIO

No chart data available.
  • DANIBIO:DC 290.6000
  • 1D
  • 1M
  • 1Y
287.6000
Interactive DANIBIO Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for DANIBIO

Danske Invest Bioteknologi Fund is an open-end fund registered in Denmark. The Fund's objective is capital appreciation, and to outperform NASDAQ's biotech-index(NBI). The Fund invests worldwide in equity of biotechnology companies, and companies closely related to the biotechnology sector.

Inception Date: 2000-05-26 Telephone: 45-3333-7171
Managers: -
Web Site: www.danskeinvest.dk

Fundamentals for DANIBIO

NAV (on 2015-04-24) 285.5100
Assets (M) (on 2015-03-31) 1,536.9740
Shares out (M) 0.00
Market Cap (M) 0.00
% Premium 1.78
Average 52-Week % Premium 1.0098
Fund Leveraged N

Dividends for DANIBIO

Dividend Type Income
Dividend Frequency Annual
Last Dividend Net (on 2014-04-25) 12.8000
Dividend Yield (ttm) 4.40%

Performance for DANIBIO

1-Month -18.07% 1-Year +74.33%
3-Month -3.29% 3-Year +40.99%
Year To Date +8.64% 5-Year +26.74%
Expense Ratio 1.50

Top Fund Holdings for DANIBIO

Filing Date: 02/28/2015
Name Position Value % of Total
Pharmacyclics Inc 41,351 59,403,668 4.553%
Intercept Pharmaceuticals Inc 39,959 58,850,158 4.511%
Novavax Inc 883,892 53,806,477 4.124%
Celldex Therapeutics Inc 296,557 50,389,881 3.862%
Biogen Inc 17,055 46,474,564 3.562%
Seattle Genetics Inc 191,857 46,270,045 3.546%
Incyte Corp 80,961 46,241,341 3.544%
Charles River Laboratories Int 88,271 45,025,420 3.451%
United Therapeutics Corp 42,674 44,019,934 3.374%
Quintiles Transnational Holdin 101,010 43,667,501 3.347%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil